Gyre Therapeutics, Inc. (GYRE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-115.1%

-$0.71

vs $4.73 price

Levered DCF

-$1.74

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

8.69

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	125.4×	86.43×	-16.87×	265×	-4.76×	-32.3×	-23.16×	-44.16×
P/B	5.95×	16.26×	-98.95×	14.15×	10.18×	23.86×	17.94×	11.06×
P/S	5.41×	9.74×	13.8×	5.88×	57×	86.66×	0×	221,193.86×
EV / EBITDA	35.15×	57.22×	75.42×	54.75×	-4.29×	-31.85×	-22.04×	-38.32×
Gross margin	95.4%	96.3%	95.9%	95.3%	-4.5%	56.3%	0.0%	-2383.3%
Operating margin	9.9%	15.3%	-59.3%	9.0%	-1141.0%	-273.9%	0.0%	-563700.0%
Net margin	4.3%	11.4%	-81.9%	2.3%	-1198.3%	-265.1%	0.0%	-500916.7%
Current ratio	5.6×	3.32×	2.85×	4.06×	3.63×	5.03×	3.32×	25.83×
Debt / equity	0.01×	0.03×	-0.03×	0.01×	0.06×	0.02×	0.03×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	15.1%	269.8%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	-255.0%	70524.5%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	4.7%	19.1%	587.1%	5.4%	-214.0%	-73.0%	-80.7%	-25.1%
Return on invested capital	5.3%	11.7%	-69.5%	5.8%	-192.6%	-72.9%	-81.7%	-28.2%
Return on assets	3.0%	9.6%	-79.7%	2.7%	-158.0%	-58.6%	-56.0%	-24.1%
Free cash flow yield	-0.0%	-0.7%	1.1%	0.9%	-20.2%	-3.0%	-3.6%	-2.2%
Earnings yield	0.8%	1.2%	-5.9%	0.4%	-21.0%	-3.1%	-4.5%	-2.3%
Enterprise value	$594.6M	$1B	$1.5B	$577.1M	$376.3M	$1.8B	$1.2B	$1.3B
Net debt / EBITDA	-2.14×	-0.57×	-1.63×	-2.33×	0.48×	0.51×	0.25×	0.92×
Cash conversion cycle (days)	793	686	363	513	-172	-179	-10,698	-3,057